Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF



    AURORA, Ontario, June 23 /CNW/ -- Helix BioPharma Corp. (TSX, FSE: HBP;
OTCQX: HXBPF) announced today that it has commenced trading in the U.S. on the
OTCQX International Market under the ticker symbol HXBPF.  Investors can find
real-time quotes, disclosure and financial information about the OTCQX
International Market at www.otcqx.com.

    "Our OTCQX listing provides Helix with enhanced local access to the
largest capital market in the world," said John Docherty, president and chief
operating officer of Helix.  "Following our recently announced 20-F SEC
registration, our OTCQX listing is another important steppingstone towards our
ultimate goal of a listing on a major U.S. stock exchange such as The NASDAQ."

    U.S. investment bank, Merriman Curhan Ford, will serve as Helix's
Principal American Liaison ("PAL") on the OTCQX and will be responsible for
providing guidance on the Company's continuing OTCQX-listing requirements and
arranging a comprehensive suite of U.S. capital market services.

    "Merriman is very pleased to sponsor Helix and to serve as their PAL,"
said Stephen Nash, managing director and head of Merriman Curhan Ford's OTCQX
Advisory Group.  "With our leadership in the advising, financing and trading
of small capitalization health care companies, Merriman is uniquely positioned
to help raise this exciting company's profile amongst U.S. investors."
    

    About Helix BioPharma Corp.
    
    Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy.  The Company is actively developing innovative
products for the prevention and treatment of cancer based on its proprietary
technologies.  Helix's product development initiatives include its Topical
Interferon Alpha-2b and its novel L-DOS47 new drug candidate.  Helix is listed
on the TSX and FSE under the symbol "HBP" and on the OTCQX International
Market under the symbol "HXBPF".
    

    About Merriman Curhan Ford
    
    Merriman Curhan Ford (Nasdaq:   MERR) is a financial services firm focused
on fast-growing companies and the institutions that invest in them. The
company offers high-quality investment banking, equity research, institutional
services and corporate & venture services, and specializes in five growth
industry sectors: CleanTech, Consumer/Internet/Media, Health Care, Natural
Resources and Technology.  For more information, please go to www.mcfco.com.
    

    About OTCQX
    
    The OTCQX marketplace, operated by Pink OTC Markets Inc., is the premier
tier of the U.S. over-the-counter market.   OTCQX provides a gateway to U.S.
securities markets for international companies that are listed on a qualified
non-U.S. exchange and provide ongoing disclosure in English to U.S. investors.
More importantly, OTCQX distinguishes the reputable international issuers from
the 9,000 over-the-counter securities traded in the U.S. Only leading
companies that have substantial operating businesses and provide credible
disclosure to the public are eligible for inclusion on the premium-tier OTCQX,
which commenced trading on March 5, 2007.  For more about OTCQX, visit
www.otcqx.com.


    For further information contact:

    
    Investor & Media Relations
    Ian Stone
    Russo Partners LLC
    Tel:  (619) 814-3510
    Fax:  (619) 955-5318
    Email:  ian.stone@russopartnersllc.com
    

    
    Robert Flamm, Ph.D.
    Russo Partners LLC
    Tel:  (212) 845-4226
    Email: robert.flamm@russopartnersllc.com
    www.russopartnersllc.com

    
    Helix BioPharma Corp. ("Helix" or the "Company") has relied solely on
Merriman Curhan Ford and OTCQX for the information about them, respectively,
provided in this News Release and the Company disclaims any liability with
respect to such information.  Helix disclaims responsibility or liability for
information contained in any linked or referenced website, and such links and
references do not constitute an endorsement by Helix of such websites. This
News Release contains certain forward-looking statements and information
regarding Helix's OTCQX listing, its relationship with Merriman Curhan Ford,
its ultimate goal of listing on a major U.S. stock exchange and its product
development, which statements and information can be identified by the use of
forward-looking terminology such as "towards," "goal", "developing", "will
be", "to help" or variations thereon, or comparable terminology referring to
future events or results. Forward looking statements and information are
statements and information about the future and are inherently uncertain.
Helix's actual results could differ materially from those anticipated in these
forward-looking statements and information as a result of numerous risks and
uncertainties including without limitation: uncertainty whether Helix's shares
will ultimately be listed on a major U.S. exchange, whether Nasdaq or
otherwise, due to the fact that it does not currently meet the minimum listing
requirements of any such exchange and may never meet them or if it does, it
may not be accepted for listing on any such exchange;  uncertainty whether the
Company's U.S. investor profile will be raised amongst U.S. investors, which
may not occur due to a number of factors including potential lack of demand
for Helix's shares, the fact that Helix's shares will be "penny stock" and
subject to certain restrictions, and the state of the financial and stock
markets generally; Helix's dependency on Merriman Curhan Ford for performance
and the possibility that the relationship of the parties may terminate early;
uncertainty whether Helix's shares will continue to be listed on the OTCQX;
uncertainty whether the Company's products under development, including
Topical Interferon Alpha-2b and L-DOS47 will be successfully developed and
commercialized as a drug or at all; the need for additional clinical trials,
the occurrence and success of which cannot be assured; product liability and
insurance risks; research and development risks; the risk of technical
obsolescence; the need for further regulatory approvals, which may not be
obtained in a timely manner or at all; intellectual property risks;
marketing/manufacturing and partnership/strategic alliance risks; the effect
of competition; uncertainty of the size and existence of a market opportunity
for Helix's products; as well as a description of other risks and
uncertainties affecting Helix and its business, as contained in news releases
and filings with the securities regulatory authorities, including its latest
Annual Information Form, at www.sedar.com and Form 20-F at
www.sec.gov/edgar.shtml, any of which could cause actual results to vary
materially from current results or Helix's anticipated future results.
Forward-looking statements and information are based on the beliefs,
assumptions, opinions and expectations of Helix's management at the time they
are made, and Helix does not assume any obligation to update any
forward-looking statement or information should those beliefs, assumptions,
opinions or expectations, or other circumstances change, except as required by
law.
    




    




For further information:

For further information: Investor & Media Relations, Ian Stone,
+1-619-814-3510, fax +1-619-955-5318, ian.stone@russopartnersllc.com; or
Robert Flamm, Ph.D., +1-212-845-4226, robert.flamm@russopartnersllc.com, both
of Russo Partners LLC for Helix BioPharma Corp

Organization Profile

HELIX BIOPHARMA CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890